Attached files

file filename
XML - IDEA: XBRL DOCUMENT - CytoCore IncR22.htm
EXCEL - IDEA: XBRL DOCUMENT - CytoCore IncFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - CytoCore IncR8.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR6.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR9.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR2.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR31.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR33.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR35.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR28.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR32.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR37.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR30.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR29.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR25.htm
EX-32.1 - EXHIBIT 32.1 - CytoCore Incv326519_ex32-1.htm
EX-31.1 - EXHIBIT 31.1 - CytoCore Incv326519_ex31-1.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR5.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR1.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR4.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR3.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR24.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR19.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR20.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR27.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR21.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR36.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR12.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR13.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR14.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR16.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR17.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR10.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR34.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR18.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR38.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR23.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR15.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR26.htm
10-Q - FORM 10-Q - CytoCore Incv326519_10q.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR11.htm
v2.4.0.6
Organization
9 Months Ended
Sep. 30, 2012
Organization [Abstract]  
Organization
Note 1.Organization

 

CytoCore, Inc. (“CCI” or the “Company”) was incorporated in Delaware in December 1998. Except where the context otherwise requires, “CCI,” the “Company,” “we” and “our” refers to CytoCore, Inc. and our subsidiaries and predecessors.

 

Currently, CCI has one product of its own for sale – its SoftPap collector. CCI is developing, and plans to sell an integrated family of cost-effective products for the detection, diagnosis and treatment of cancer under the trade name of CytoCore Solutions®. CytoCore Solutions products are intended to address sample collection, specimen preparation, specimen evaluation (including detection/screening and diagnosis), treatment and patient monitoring within vertical markets related to specific cancers. Current CytoCore Solutions products are focused upon cervical cancer. CCI plans that this focus will later be expanded to include other gynecological cancers as well as bladder, lung, and breast cancers, among others. Within each of these markets CCI anticipates that the CytoCore Solutions products will be sold as individual value-added drop-in replacements for existing products and as integrated systems that improve the efficiency and effectiveness of clinical and laboratory operations.

 

The Company has also began marketing and selling a companion product which is designed to detect breast cancer. This product is manufactured by a third party. The Company has recorded sales totaling $176,000 for the nine months ended September 30, 2012.

 

The Company has incurred significant operating losses since its inception. Management expects that significant on-going operating expenditures will be necessary to successfully implement CCI’s business plan and develop, manufacture and market its products. These circumstances raise substantial doubt about CCI’s ability to continue as a going concern. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to increase sales of its products, develop new products, and raise additional capital. At September 30, 2012, the Company did not have any cash to fund its operations.

 

If the Company is unable to obtain adequate additional financing or generate sufficient sales revenues, it will be unable to continue its product development efforts and other activities and will be forced to curtail or cease operations. The consolidated financial statements presented herein do not include any adjustments that might result from the outcome of this uncertainty.